Validation of a Genomic Classifier in the NRG Oncology/RTOG 0521 Phase III Trial of Docetaxel with Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer.
Saved in:
| Title: | Validation of a Genomic Classifier in the NRG Oncology/RTOG 0521 Phase III Trial of Docetaxel with Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer. |
|---|---|
| Authors: | Phillips, R.1 (AUTHOR), Proudfoot, J.2 (AUTHOR), Davicioni, E.2 (AUTHOR), Spratt, D.E.3 (AUTHOR), Feng, F.Y.4 (AUTHOR), Simko, J.5 (AUTHOR), Den, R.B.6 (AUTHOR), Pollack, A.7 (AUTHOR), Rosenthal, S.A.8 (AUTHOR), Sartor, O.9 (AUTHOR), Sweeney, C.10 (AUTHOR), Attard, G.11 (AUTHOR), Patel, S.I.12 (AUTHOR), Hall, W.A.13 (AUTHOR), Efstathiou, J.A.14 (AUTHOR), Shah, A.B.15 (AUTHOR), Hoffman, K.E.16 (AUTHOR), Pugh, S.17 (AUTHOR), Sandler, H.M.18 (AUTHOR), Tran, P.T.19 (AUTHOR) |
| Source: | International Journal of Radiation Oncology, Biology, Physics. 2023 Supplement, Vol. 117 Issue 2, pS34-S35. 2p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
